Voyager Q2 FY26 net loss narrows to $24.47 million; revenue falls to $3.17 million
VYGR•Q2 FY26 results
Voyager posted a Q2 net loss of USD 24.5 million, narrowing from USD 33.4 million a year earlier.
Revenue fell 39.1% from a year earlier to USD 3.2 million, on lower Neurocrine collaboration revenue as activities moved beyond research.
Pipeline updates
VY7523 tau PET imaging data are expected in Q4 2026.
VY1706 dosing is expected to begin in Q4 2026 after FDA IND clearance.
Expenses and cash position
R&D expenses dropped 29.7% to USD 22 million, reflecting program and platform prioritization.
Cash, cash equivalents, and marketable securities totaled USD 148.8 million at June 30, with runway projected into 2028.
